A major head-to-head study found that people lost significantly more weight with Eli Lilly's diabetes drug Mounjaro compared to Novo Nordisk's Ozempic, despite similar side effects, dropout rates, and diabetes benefits. Both drugs belong to the GLP-1 class, but Lilly's drug, tirzepatide, has an additional action that enhances its effectiveness. The study, which involved over 18,000 patients, highlighted the superior weight loss results of tirzepatide. Click here for article.
Weight Loss Efficacy: People on tirzepatide were more likely to achieve significant weight loss milestones compared to those on semaglutide, with tirzepatide showing superior results at 3, 6, and 12 months.
Side Effects and Dropout Rates: Both drugs had similar side effects, mainly gastrointestinal, leading to high dropout rates (56% for tirzepatide and 53% for semaglutide).
Study Demographics: The study included a diverse group of patients, but most participants were middle-class white women, with those on tirzepatide being even more likely to be white and female.
Access and Cost Issues: High costs and supply constraints hinder access to both medications, particularly for Black, Hispanic, and Native women, who have higher rates of obesity and diabetes but face more barriers to coverage for these treatments.
Comments